Search Result

Results for "

NOP agonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) CD20 (1) Opioid Receptor (28)
By Research Areas:	Cancer (4) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (24)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak *NOP* affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-15536

Cebranopadol Maximum Cited Publications 7 Publications Verification GRT6005	Opioid Receptor	Neurological Disease Cancer
Cebranopadol is an analgesic *NOP* and opioid receptor agonist with K_is/EC₅₀s of 0.9 nM/13 nM, 0.7 nM/1.2 nM, 2.6 nM/17 nM, 18 nM/110 nM for human NOP, MOP, KOP and delta-opioid peptide (DOP) receptor, respectively.

HY-156993

NOP agonist-2	Opioid Receptor	Metabolic Disease
NOP agonist-2 is a selective *NOP* agonist .

HY-156992

AT-035	Opioid Receptor	Neurological Disease
AT-035 is a high affinity and selective *NOP* agonist .

HY-156972

NOP agonist-1	Opioid Receptor	Metabolic Disease
NOP agonist-1(compound 4) is a nociceptin opioid receptor (NOP) partial agonist. NOP agonist-1attenuate parkinsonian disabilities in 6-OHDA hemilesioned rats .

HY-118987

AT-127	Opioid Receptor	Neurological Disease
AT-127 is a NOP receptor partial agonist, stimulating NOP/G-protein interaction in a concentration dependent manner .

HY-P1319

Nociceptin(1-7)	Opioid Receptor	Inflammation/Immunology
Nociceptin (1-7) is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) is a potent *ORL₁ (NOP)* receptor agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo .

HY-19467

SCH 486757	Opioid Receptor	Neurological Disease
SCH 486757 is an orally effective pain peptide receptor (NOP) agonist. SCH 486757 can be used for the study of cough .

HY-122681

SR-16435	Opioid Receptor	Neurological Disease
SR-16435 is a nociceptin/orphanin FQ (NOP)/μ-opioid receptor partial agonist, with high binding affinity (NOP receptor K_i=7.49; μ-Opioid receptor K_i=2.70). SR-16435 can relieve pain .

HY-P1319A

Nociceptin(1-7) TFA	Opioid Receptor	Inflammation/Immunology
Nociceptin (1-7) TFA is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) TFA is a potent *ORL₁ (NOP)* receptor agonist with antinociceptive activity. Nociceptin (1-7) TFA combines with nociceptin reduces hyperalgesia in vivo .

HY-107722

SCH 221510	Opioid Receptor	Neurological Disease
SCH 221510 is a potent, orally active and selective *NOP* (nociceptin opioid receptor) agonist, with an EC₅₀ of 12 nM and K_i of 0.3 nM. SCH 221510 shows an anxiolytic-like effect .

HY-107094

MT-7716 hydrochloride W-212393 hydrochloride	Opioid Receptor	Neurological Disease
MT-7716 hydrochloride (W-212393 hydrochloride) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention .

HY-10886

MCOPPB	Opioid Receptor	Neurological Disease
MCOPPB is an orally active and selective agonist of Nociceptin/Orphanin FQ–Receptor. MCOPPB inhibits signaling through the NOP receptor in the mouse brain. MCOPPB is used in anxiety disorders research .

HY-107094A

MT-7716 free base W-212393	Opioid Receptor	Neurological Disease
MT-7716 free base (W-212393) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention .

HY-107743

Naloxone benzoylhydrazone NalBzoH	Opioid Receptor	Neurological Disease
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic κ3-opioid receptor agonist, and a partial agonist at the cloned μ and δ opioid receptors, and an antagonist at *opioid-like NOP* receptors**. Naloxone benzoylhydrazone has potently analgesia effect .

HY-P1301

[Arg14,Lys15]Nociceptin	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC₅₀ of 1 nM. [Arg14,Lys15]Nociceptin displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-12844

Ro 64-6198 1 Publications Verification	Opioid Receptor	Neurological Disease
Ro 64-6198 is a potent, selective, nonpeptide, high-affinity, high cellular permeability and brain penetration N/OFQ receptor (NOP) agonist with an EC₅₀ value of 25.6 nM. Ro 64-6198 is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 can be used for stress and anxiety, addiction, neuropathic pain, cough, and anorexia .

HY-15536R

Cebranopadol (Standard)	Opioid Receptor	Neurological Disease Cancer
Cebranopadol (Standard) is the analytical standard of Cebranopadol. This product is intended for research and analytical applications. Cebranopadol is an analgesic NOP and opioid receptor agonist with Kis/EC50s of 0.9 nM/13 nM, 0.7 nM/1.2 nM, 2.6 nM/17 nM, 18 nM/110 nM for human NOP, MOP, KOP and delta-opioid peptide (DOP) receptor, respectively.

HY-P1301A

[Arg14,Lys15]Nociceptin TFA	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin TFA is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC₅₀ of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-15536B

Cebranopadol hemicitrate GRT6005 hemicitrate	Opioid Receptor	Neurological Disease Cancer
Cebranopadol hemicitrate is an analgesic *NOP* and opioid receptor agonist with K_is/EC₅₀s of 0.9 nM/13 nM, 0.7 nM/1.2 nM, 2.6 nM/17 nM, 18 nM/110 nM for human NOP, MOP, KOP and delta-opioid peptide (DOP) receptor, respectively. Cebranopadol hemicitrate can be used for acute and chronic pain study .

HY-13101B

(S)-MCOPPB	Opioid Receptor	Neurological Disease
(S)-MCOPPB is the S-form of MCOPPB (HY-13101). MCOPPB is an orally active and selective agonist of Nociceptin/Orphanin FQ-Receptor. MCOPPB inhibits signaling through the NOP receptor in the mouse brain. MCOPPB can be used for anxiety disorders study .

HY-P1316

Ac-RYYRWK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors .

HY-P1316A

Ac-RYYRWK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d of 0.071 nM, but has no affinity for μ-, κ- or δ-opioid receptors .

HY-128865

BPR1M97	Opioid Receptor	Neurological Disease
BPR1M97 is a dual-acting mu opioid receptor (MOP) and *nociceptin-orphanin FQ peptide (NOP) receptor* agonist with K_i values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects .

HY-121974

SR14150	Opioid Receptor	Neurological Disease
SR14150 is a partial agonist of the NOP receptor with high affinity. The biological activity of SR14150 makes it potentially useful for the development of a new generation of multi-target opioids designed to simultaneously improve analgesia and reduce side effects. The activity of SR14150 and its interaction with other opioid receptors may provide new inhibitory options for the management of chronic pain .

HY-P1300

[(pF)Phe4]Nociceptin(1-13)NH2	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective NOP receptor (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀ of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P1302

Orphanin FQ(1-11)	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice .

HY-P1300A

[(pF)Phe4]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 TFA is a highly potent and selective NOP receptor (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀ of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 TFA displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P1302A

Orphanin FQ(1-11) TFA	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) TFA is analgesic in CD-1 mice .

Cat. No.	Product Name	Target	Research Area

HY-P1302

Orphanin FQ(1-11)	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice .

HY-P1319

Nociceptin(1-7)	Opioid Receptor	Inflammation/Immunology
Nociceptin (1-7) is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) is a potent *ORL₁ (NOP)* receptor agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo .

HY-P1319A

Nociceptin(1-7) TFA	Opioid Receptor	Inflammation/Immunology
Nociceptin (1-7) TFA is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) TFA is a potent *ORL₁ (NOP)* receptor agonist with antinociceptive activity. Nociceptin (1-7) TFA combines with nociceptin reduces hyperalgesia in vivo .

HY-P1301

[Arg14,Lys15]Nociceptin	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC₅₀ of 1 nM. [Arg14,Lys15]Nociceptin displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-P1301A

[Arg14,Lys15]Nociceptin TFA	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin TFA is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC₅₀ of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-P1316

Ac-RYYRWK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors .

HY-P1316A

Ac-RYYRWK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d of 0.071 nM, but has no affinity for μ-, κ- or δ-opioid receptors .

HY-P1300

[(pF)Phe4]Nociceptin(1-13)NH2	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective NOP receptor (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀ of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P1302A

Orphanin FQ(1-11) TFA	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) TFA is analgesic in CD-1 mice .

Cat. No.	Product Name	Target	Research Area

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak *NOP* affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: